Public health policies and management strategies for genital Chlamydia trachomatis infection by Shaw, Kelly et al.
© 2011 Shaw et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Risk Management and Healthcare Policy 2011:4 57–65
Risk Management and Healthcare Policy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
57
Review
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/RMHP.S12710
Public health policies and management strategies 
for genital Chlamydia trachomatis infection
Kelly Shaw1,2
David Coleman1
Maree O’Sullivan1
Nicola Stephens3
1Department of Health and Human 
Services, Hobart, Tasmania, Australia; 
2Health and wellbeing Research 
Cluster, Southern Cross University, 
New South wales, Australia; 3NSw 
Health, Sydney, New South wales, 
Australia
Correspondence: Kelly Shaw 
Health and wellbeing Research Cluster, 
Southern Cross University, Hogbin Drive, 
Coffs Harbour 2450, NSw, Australia 
Tel +61 2 6659 3626 
email kelly.shaw@scu.edu.au
Abstract: Genital Chlamydia trachomatis is a sexually transmissible bacterial infection 
that is asymptomatic in the majority of infected individuals and is associated with significant 
short-term and long-term morbidity. The population prevalence of the infection appears to be 
increasing. C. trachomatis is of public health significance because of the impacts of untreated 
disease on reproductive outcomes, transmission of other sexually acquired infections, and the 
costs to health systems. At the individual level, C. trachomatis infection is readily treatable 
with antibiotics, although antibiotic resistance appears to be increasing. At the population level, 
public health control of spread of infection is more problematic. Approaches to control include 
primary preventive activities, increased access to testing and treatment for people with or at risk 
of infection, partner notification and treatment, and screening either opportunistically or as part 
of an organized population screening program. A combination of all of the above approaches is 
likely to be required to have a significant effect on the burden of disease associated with genital 
chlamdyia infection and to reduce population prevalence. The development of a vaccine for 
genital chlamydia infection could significantly reduce the public health burden associated with 
infection; however a vaccine is not expected to be available in the near future.
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Introduction
Chlamydia trachomatis is a gram-negative bacterium whose sexually transmissible 
strains D to K cause largely asymptomatic genital tract infections in males and females.1 
These strains of C. trachomatis can also cause sexually transmissible rectal and, rarely, 
pharyngeal infections. Strains 1.1, 1.2, and 1.3 cause lymphogranuloma venereum, 
a sexually transmissible infection responsible for outbreaks of ulcerative proctitis 
which may be associated with inguinal and pelvic abscesses and anal strictures; the 
infection more commonly affects men who have sex with men.2
Risk factors for contracting C. trachomatis infection include having multiple 
sexual partners, having a new sexual partner, inconsistently using barrier contracep-
tives, having a history of previous or coexistent sexually transmissible infections, age 
(those aged 15 to 24 years most affected) and race.1,3 The likelihood of transmission 
of C. trachomatis per act of unprotected intercourse is between 30% and 50%; in 
heterosexual couples the likelihood of a long-term sexual partner becoming infected 
is approximately 66%.4–6
In women, C. trachomatis commonly results in cervicitis and urethritis; up to 
40% of untreated cases progress to pelvic inflammatory disease.7 Of those with pelvic 
inflammatory disease, up to 20% become infertile, 18% develop chronic pelvic pain, Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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and 9% may have a tubal pregnancy.8,9 Chlamydia infection 
may also increase the risk for cervical cancer.10
In men, chlamydia infection can cause nongonococcal 
urethritis, acute epididymitis and, rarely, may result in ure-
thral strictures and/or Reiters Syndrome. In males, chlamydia 
urethritis may also be associated with male infertility.8,11,12
C. trachomatis may be associated with adverse pregnancy 
outcomes for both mother and child, including miscarriage, 
preterm labor, premature rupture of the membranes, and low 
birthweight.13 Chlamydia cervicitis may be associated with 
neonatal conjunctivitis, nasopharyngitis, and pneumonia.
A major concern with chlamydia infections is that 70% 
to 85% of infected women and over 50% of infected men 
are asymptomatic.14,15
However, undiagnosed infection does not always result 
in serious complications. The natural history of untreated 
lower genital tract C. trachomatis infection in women is 
one of spontaneous clearance within 2 to 3 years of between 
30% and 50%.16 In order for tubal scarring to occur, chronic 
persistent infection or frequent re-infection appears to be 
necessary.12
Epidemiology
Although C. trachomatis is considered the most preva-
lent sexually transmissible infection worldwide, its true 
prevalence is unknown. The World Health Organization 
estimates that each year almost 100 million new cases occur 
worldwide.17
The prevalence of C. trachomatis reported in countries 
internationally varies widely among populations. Age is 
the strongest predictor of risk. A systematic review of 
C.   trachomatis among asymptomatic European women 
estimated the prevalence to be up to 17% in some population 
groups and is particularly elevated among young women 
attending sexual health clinics.18 In population cohorts under 
30 years of age in Denmark, the Netherlands, and the UK the 
prevalence has been estimated at between 2% and 6%.19–21
Most epidemiological studies have been conducted 
in developed countries. As a result, the prevalence of the 
infection in populations in less developed countries is poorly 
understood.22
Some research suggests that the prevalence of genital 
C. trachomatis infections is increasing over time. However, 
increasing prevalence is difficult to establish definitively due 
to the need to control for testing effort and the effects of new 
testing methods in analysing rates of infection.23
The incidence rate of new infections of genital C.   trachomatis 
is even more difficult to determine. Few studies have   examined 
the incidence of the infection as, in order to determine the 
  incidence of the infection, large population cohorts need to 
be tested at regular intervals.24
Public health significance
Chlamydia is a significant public health problem because 
of the impact of untreated genital chlamydia infection on 
rates of pelvic inflammatory disease, subfertility and poor 
reproductive outcomes, the association between the infection 
and the transmission of other sexually transmissible infec-
tions, and the impacts of the burden of disease associated 
with genital chlamydia infection on health services costs. 
Although inexpensive and effective treatment is available, 
control of chlamydia is challenging since most people with 
genital chlamydia infection are asymptomatic.
Chlamydia is costing health care systems billions of 
dollars to treat not only the acute infections, but also the 
complications they cause.25 In particular, the costs of treat-
ing subfertility due to chlamydia are high as tubal surgery 
and in vitro fertilization are expensive. The cost of treating 
the complications of undiagnosed C. trachomatis infection, 
including pelvic inflammatory disease and tubal infertility, 
are high both in psychosocial and in financial terms.24
As with other inflammatory sexually transmissible infec-
tions, chlamydia infection facilitates the transmission of HIV 
infection in both males and females.26
Management strategies
Clinical treatment of the infected 
individual
Once diagnosed, C. trachomatis is easily and effectively 
treated with antibiotics. The current recommended treat-
ments for genital tract infections caused by C. trachomatis 
are azithromycin or doxycycline. Azithromycin is preferred 
because of it being a single 1-g dose compared with a 7-day 
course of doxycycline, thereby enhancing compliance.27 
Ofloxacin, minocycline, lymecycline, and erythromycin are 
alternative treatments, but are generally not used as regi-
mens extend over 7 days, some are less well tolerated, and 
the likelihood of noncompletion of treatment is higher.28
Without antibiotics, clearance of genital chlamydia 
infection is poor; studies on the natural course of untreated 
C. trachomatis lower genital tract infections in women show 
spontaneous clearance rates of 30% to 50% in the first 2 to 
3 years.29,30
There is emerging evidence that C. trachomatis is devel-
oping antibiotic resistance, with some clinical isolates having 
single and multidrug resistance when cultured in vitro.31–33 Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
59
Public health policies and strategies for Chlamydia control
Further, while a shortened duration of infection from early 
antibiotic treatment reduces infection-associated reproduc-
tive sequelae, the number of cases continues to increase.34 
Researchers have suggested that this increase is occurring 
because early intervention with antibiotics interferes with 
the development of protective immune responses, thereby 
increasing the risk of reinfection, which has been termed the 
arrested immunity hypothesis.34
The effects of this phenomenon on public health 
approaches to control of genital chlamydia infection are yet 
to be explored. Further, there is widespread use of nucleic 
acid amplification testing (NAAT) to detect infection. If 
resistance is developing, monitoring the development of this 
requires laboratory testing in addition to NAAT.
Testing people with genital chlamydia infection for 
the presence of other sexually transmissible infections is 
important. Coinfection with other sexually transmissible 
infections occurs with variable frequency among people 
with genital chlamydia infection. In some countries, a high 
prevalence of coinfection of chlamydia and gonorrhoea 
has been observed. Risk appears to be increased among 
people with genital chlamdyia who have higher numbers 
of sexual partners, are aged between 15 and 19 years, are 
in juvenile detention centers, are attending sexual health 
clinics, and among men who have unprotected sex with 
other men.35,36
Public health approaches to control
The spread of a sexually transmissible infection within a 
population is dependent on the probability of transmission 
of the pathogen from an infected to a susceptible individual, 
the rate of contact between infected and susceptible indi-
viduals, and how long the infection persists.7 Controlling 
chlamydia therefore requires interventions to reduce each 
of these factors.
Some factors are more easily influenced than others. 
The probability of transmission can be reduced by the use 
of condoms and the contact rate can be reduced by having 
fewer sexual partners and concurrent partnerships.7 A par-
ticular public health goal for chlamydia control is reducing 
the duration of infection; as most infected individuals are 
asymptomatic they are less likely to present to clinical 
services for diagnosis and treatment. The infected person 
can therefore remain infectious for a long period and can 
continue to transmit the infection to their sexual partners 
until the infection spontaneously resolves.
The range of activities required for control of genital 
chlamdyia infection includes:
•	 primary prevention involving people at risk of acquiring 
and transmitting the infection; primary preventive activi-
ties include sexual health and relationships education;
•	 the promotion of safer sex and condom use;
•	 effective diagnosis and treatment of those with 
infection; and
•	 identifying and treating partners of infected individuals.
Public health initiatives aimed at influencing social and 
environmental determinants of health are an important com-
ponent of successful community-based health promotion. By 
necessity, policies aimed at reducing the burden of disease 
associated with chlamydia infection need to include access 
to, and quality of, healthcare services equipped to identify 
and manage people with or at risk of infection. This includes 
ensuring access to health services for minors.37
A diversity of services is required to provide comprehen-
sive access to patients with, or at risk of, infection. General 
practitioners are a mainstay of provision of assessment and 
management. Sexual health services, family planning, obstet-
rics and gynecology services, and general hospitals also play an 
important role in providing assessment and management.38
Primary prevention
Chlamydia is a risk for all young people who are sexually 
active. As a result, population-wide information and edu-
cation forms the basis of primary preventive activities for 
chlamydia control.39 Countries with pragmatic school-based 
sexual health education policies have been shown to have 
better sexual health-related statistics among school-aged 
people than countries that do not.40
Primary preventive activities need to be well designed, 
long-term, and research-based in order to be effective.41 
There is some evidence that the most successful sexual 
health promotion strategies are those that acknowledge 
the social and media influences on young people and use 
these to help strengthen group norms around safe sexual 
behavior.42
Primary prevention of chlamydia infection is a fre-
quent health and social policy initiative of governments 
  internationally. The World Health Organization recommends 
that countries implement evidence-based strategies for pri-
mary prevention and surveillance of sexually transmissible 
infections.22 Governments have invested in campaigns for 
safer sex to increase awareness of risk behaviors.43
Partner notification and treatment
Partner notification and treatment is a common strategy 
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the highest prevalence of chlamydia infection occurs in the 
partners of patients with diagnosed chlamydia infection.28 
However, partner notification reaches less than 60% of 
partners.44
Randomized controlled trials assessing the impact of 
partner notification and treatment for chlamydia have shown 
variable impacts on the recurrence or persistence of chla-
mydia infection in index patients. Some studies have found 
statistically significant reductions; others have found a trend 
towards decreased infection but this did not reach statistical 
significance.45
Published guidelines internationally recommend refer-
ral of sexual partners for screening and possible treatment. 
Recommendations regarding the time period for identifying 
previous partners differs slightly; the British Association 
for Sexual Health and HIV provides recommendations 
according to whether the index patient is symptomatic or 
asymptomatic, recommending a 4-week look-back period 
for symptomatic index cases, and an arbitrary cut-off of 
6 months for asymptomatic index patients (or until the most 
recent sexual partner).46 The Scottish Intercollegiate Guide-
lines Network (SIGN) makes similar recommendations, but 
takes index patient gender into account, recommending a 
4-week look-back period for men with symptomatic infec-
tion and a cut-off of 6 months for women and asymptomatic 
men (or until the most recent sexual partner).47 Australasian 
guidelines recommend contact tracing for 6 months before 
identification of chlamydia infection.4
The US Centers for Disease Control and Prevention 
(CDC) recommends that sex partners be evaluated, tested, 
and treated if they had sexual contact with an infected patient 
during the 60 days before onset of symptoms or diagnosis. 
However, they also recommend evaluation and treatment of 
the last sexual contact, even if that contact was more than 
60 days before symptom onset.48
CDC and SIGN address patient delivered partner 
medication (PDPM). The groups agree that some evidence 
demonstrates that it can reduce the risk of persistent or 
recurrent infection in patients with chlamydia compared 
with standard partner referral. SIGN notes, however, that 
PDPM cannot currently be carried out in the UK because of 
legal considerations. These include the uncertain legal status 
of the practice of medical and pharmacy boards in some 
countries, uncertainties regarding the duty of care of treating 
clinicians to assess patients before dispensing medications 
with the potential for adverse effects, and the lack of inves-
tigation of risk factors for coinfection.49,50 CDC discusses 
PDPM for use only in heterosexual sexual   partnerships. 
They add that   patient-delivered partner therapy is not 
routinely   recommended for men who have sex with men 
because of a high risk for coexisting infections, especially 
undiagnosed HIV infection, in their partners.
Presumptive treatment
Periodic treatment given for a presumed infection, in the 
absence of investigations to confirm presence of infection, 
has been proposed as a strategy to reduce the prevalence of 
infections in populations who are at risk. However, results 
of studies examining this approach have failed to establish 
its effectiveness. Randomized trials of monthly antibiotics 
provided to sex workers did not uniformly demonstrate a 
reduction in the incidence of chlamydia infections.51 A ran-
domized trial comparing prophylaxis with a screen and treat 
strategy for chlamydia management in patients presenting 
for termination of pregnancy demonstrated that prophylaxis 
was as effective and more cost effective.52 Mathematical 
modeling to estimate the impact of periodic presumptive 
treatment on the transmission of genital chlamydia infection 
by female sex workers has shown significant decreases in the 
prevalence of genital chlamydia with .30% coverage of the 
sex worker population.53
Disadvantages of prophylactic treatment are that partner 
notification and treatment does not occur, reducing the oppor-
tunity to limit population spread of the infection.
Self-testing with point-of-care tests
Point-of-care tests provide people with a rapid test that can 
be used to self-test for the presence of chlamydia infection. 
These tests have a reported sensitivity of 52% to 80%, speci-
ficity of 97% to 99%; lower than reported sensitivity and 
specificity of NAAT available through laboratories.28
There is currently insufficient evidence to demonstrate 
that using point-of-care-tests would increase the overall 
number of cases of chlamydia detected. As the sensitiv-
ity and specificity of these tests is lower than tests used in 
current practice, increased number of people incorrectly 
diagnosed, and number of contacts incorrectly traced and 
managed result from their use; for a hypothetical cohort of 
1000 people, using the current practice of NAAT would result 
in 13 people who were offered testing being correctly treated 
whereas the   point-of-care test would result in between 7 and 
11 people being correctly treated.28
Screening for genital chlamydial infection
In order to reduce the impacts of C. trachomatis infection, 
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  countries worldwide. The primary aim of screening is to reduce 
morbidity by early detection and treatment of uncomplicated 
lower genital tract infection. A secondary aim of screening is 
to reduce population prevalence of the infection.54
Screening can be population-based and systematic or 
can be opportunistic. In opportunistic screening, patients 
are offered screening whilst attending their treating health 
professional. In most countries where chlamydia screening 
guidelines exist, opportunistic screening of patients at risk 
of acquiring the infection is promoted.54,55
Different screening methods are adapted to different 
healthcare settings and different screening approaches are 
generally selected to suit the particular healthcare setting. 
For example, outpatient clinics accessed by at-risk youth 
and/or men who have sex with men may routinely screen 
all patients accessing the clinic; in contrast, screening in 
a general practice setting is more appropriately directed 
towards testing of patients in whom risk factors for genital 
chlamydia infection are present.38
A direct comparison of the recommendations presented in 
UK and US guidelines for the management of C.   trachomatis 
infection was conducted by the US National Guideline 
  Clearinghouse.55 According to current guidelines:
•	 The CDC and US Preventive Services Task Force (USP-
STF) recommend routine screening of all nonpregnant 
sexually active women aged 25 years and 24 years or 
younger respectively, as well as older nonpregnant 
women at increased risk (eg, those who have a new sex 
partner or multiple sex partners). With regard to fre-
quency of screening, CDC recommends annual screening 
in these populations. USPSTF cites the CDC recommen-
dation, but states that the optimal interval for screening 
for nonpregnant women is unknown;56,57
•	 In contrast with CDC and USPSTF guidelines, SIGN 
recommends that testing be targeted at those individuals 
identified as belonging to groups with the highest preva-
lence of infection: sexual partners of chlamydia-positive 
individuals, sexual partners of those with suspected but 
undiagnosed chlamydial infection, those who have been 
diagnosed with chlamydia in the previous 12 months, 
all patients (including men who have sex with men) 
attending genitor-urinary medicine clinics, and women 
undergoing termination of pregnancy. While SIGN does 
not recommend routine screening in sexually active 
women aged 24 years or younger, they do recommend 
that resources for chlamydia testing in women be targeted 
where prevalence is known to be highest, that is, first at 
those aged 15 to 19 and then at those aged 20 to 24;
•	 With regard to screening of pregnant women, USPSTF 
recommends screening for all pregnant women aged 24 
and younger, and for older pregnant women who are at 
increased risk. CDC states that prenatal screening of 
pregnant women can prevent chlamydial infection among 
neonates, and that pregnant women aged ,25 years are 
at high risk for infection. They add that local or regional 
prevalence surveys of chlamydial infection can be con-
ducted to confirm the utility of using these recommenda-
tions in particular settings. According to SIGN, there is 
no evidence to suggest that pregnancy alone should be 
an indication for routine testing for chlamydia;
•	 None of the groups recommends routine screening of 
sexually active men. USPSTF concluded that the current 
evidence is insufficient to assess the balance of benefits 
and harms of screening for chlamydial infection for men. 
CDC similarly found that evidence is insufficient to rec-
ommend routine screening in sexually active young men. 
However, CDC adds that screening of sexually active 
young men should be considered in clinical settings with 
a high prevalence of chlamydia (eg, adolescent clinics, 
correctional facilities, and STD clinics).
Australian guidelines not included in the National Clear-
inghouse Review recommend screening for C. trachomatis 
infection in all sexually active females under 25 years of 
age every 12 months. Screening of sexually active males is 
not supported with the exception of men who have sex with 
men, who should be screened every 12 months.58
As the objectives of a screening program not only target 
the individual level (reducing complications by early diagno-
sis and treatment), but also the public health level (reducing 
transmission within the population) sufficient program uptake 
is essential for screening to be effective.
Opportunistic screening results in variable rates of test-
ing within target populations. For example, in the US, the 
annual screening rate in sexually active 15- to 25-year-olds 
is approximately 41%.59 In Sweden, 71% of women have 
had at least one chlamydia test in a 10-year period.60 In the 
UK in 2009/10, 22.1% of 15- to 24-year-olds have been 
tested for genital chlamydia.61 In contrast, in Australia less 
than 10% of people in the target screening groups have had 
a chlamydia test.62
In comparison, a trial of population screening in the 
  Netherlands resulted in between 37% and 41% participation.21
The public health impacts of screening, both opportu-
nistic and population-based, are poorly understood and few 
studies have been performed to demonstrate public health 
effects. A US randomized controlled trial of   population Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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  screening demonstrated a 56% reduction in pelvic 
  inflammatory   disease.63 A Danish randomized trial in school 
students and young people found a 50% reduction in pelvic 
inflammatory disease that resulted from population-based 
screening. In contrast, a UK-based opportunistic screen-
ing program conducted using self-collected specimens 
in females failed to demonstrate an association between 
chlamydia screening and pelvic inflammatory disease.64 
Ecological studies in Sweden and the US have shown that 
chlamydia prevalence and complications have decreased 
after screening has been implemented. However, it is uncer-
tain whether the screening program was responsible for the 
decrease that was observed.65 Recent analysis of claims data 
also suggests that screening is associated with decreases in 
pelvic inflammatory disease.66
Even though the rates of genital tract infections continue 
to rise, there are no uniformly accepted screening practices.65 
Further, a recent systematic review has questioned the effec-
tiveness of opportunistic chlamydia screening, because there 
is little evidence in the available literature to demonstrate 
that the practice is effective.67 Screening appears to be cost-
effective when the costs related to diagnosing and treating 
the late sequelae of infection exceed or at least largely offset 
the costs related to screening people and treating positive 
cases. Systematic reviews of the cost effectiveness of screen-
ing young, asymptomatic women suggest that screening is 
cost effective, mainly because of the reduction in long-term 
health costs.68
Surveillance
Surveillance activities are an important public health man-
agement strategy for chlamydia prevention and control. If 
we are to have policies and new management strategies how 
do we measure/evaluate their effectiveness? Surveillance is 
one tool.
The primary role of public health surveillance is to guide 
the planning and evaluation of policy and programs, through 
the collection, analysis, and interpretation of statistical 
information. The main form of chlamydia surveillance is 
passive reporting of cases to health departments by doctors 
or laboratories.69,70
Passive surveillance can be established on an ongoing 
basis, provide geographic coverage, and can be performed 
using routinely collected administrative data, reducing 
resource implications. However, passive surveillance is 
biased by testing effort for infection. Also, passive surveil-
lance data do not provide information on characteristics such 
as gender and risk factors for acquiring infection.71
Passive surveillance can be supplemented through 
enhanced surveillance, the collection of additional informa-
tion on some or all notifications received through passive 
surveillance systems, or sentinel surveillance, the use of 
selected clinical sites to collect systematic data on cases of 
infection that are identified. Such data can be used to evaluate 
clinic-based initiatives, broader prevention programs, and 
help interpret trends in passive surveillance.72,73
vaccine
The development of a vaccine for genital chlamydia infection 
could significantly reduce the public health burden associated 
with infection. Results of vaccine trials have to date been 
disappointing. Multiple approaches to vaccine development 
have been trialed but immunity to the specific serovars that 
cause genital tract infection, which is long-lasting, is difficult 
to elicit. At present, it is not expected that a vaccine will be 
available within the next 10 years.1,24
Summary
Most people with genital chlamydia infection are asymp-
tomatic and remain unnoticed and untreated. People with 
untreated infection may be at risk of complications and 
determine the reservoir for onward transmission in the 
  population. Strategies for the control of infection and pre-
vention of its complications are only partially effective ie, 
primary prevention and partner notification, or are not yet 
available, ie, a vaccine. Randomized controlled trials that 
assess the effectiveness of many chlamydia control strategies 
are inconclusive or have not been performed.
Screening is an additional strategy for early detection 
and treatment of infected cases. Evidence on the impact 
of screening on the prevalence of chlamydia infections at 
a population level is still limited as is the impact on the 
prevalence of complications in screened women.
In spite of these evidence limitations, it is likely that 
a range of public health approaches to control of genital 
C. traachomatis infection need to be employed simultane-
ously in order to be effective in reducing the burden of disease 
associated with infection and to reduce population prevalence. 
The four levels of public health intervention that should be 
incorporated into chlamydia control programs include:
1.  Primary prevention: including health promotion and 
education, and access to condoms;
2.  Diagnosis and management services: ensuring the reach 
and target effectiveness of clinical services for the diag-
nosis and management of people with infection, includ-
ing those in hard-to-reach population groups at risk of Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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  infection, and provision of effective partner notification 
and management services in accordance with evidence-
based guidelines;
3.  Provision of opportunistic testing to population groups 
at risk of infection: testing may be provided via clinical 
services or through mechanisms that encourage self-
testing; and
4.  Provision of opportunistic or systematic population 
screening: although evidence is mixed, the organized 
provision of regular chlamydia testing to cover a sub-
stantial proportion of at-risk population groups is likely 
to be necessary to reduce chlamydia prevalence within 
the population.
Introducing a screening program for chlamydia needs 
to be considered with the same care as any other screening 
program, with an assessment of all the potential benefits, 
harms, and costs.
Effective resourcing and implementation of national chla-
mydia control strategies requires leadership and commitment 
from healthcare policy makers. The most appropriate national 
strategies are likely to vary across countries, and national 
strategies should be developed in consultation with profes-
sional medical organizations, and funders and providers of 
healthcare and diagnostic services. Surveillance activities are 
an essential component of holistic public health responses 
to chlamydia infection, to provide information regarding 
the success of preventive and management activities at the 
population level.
Further, interventions targeting the social determinants 
of health and their impact on chlamydia prevalence and out-
comes have not been the subject of extensive research. The 
sociodemographic characteristics of population subgroups in 
whom genital chlamydia infection is most prevalent suggest 
that holistic public health solutions targeting social determi-
nants should also form the basis of public health policies for 
chlamydia prevention and control.
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